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The acute phase response is generated by an overwhelming immune-inflammatory 
process against infection or tissue damage, and represents the initial response of the 
organism in an attempt to return to homeostasis. It is mediated by acute phase proteins 
(APPs), an assortment of highly conserved plasma reactants of seemingly different func-
tions that, however, share a common protective role from injury. Recent studies have 
suggested a crosstalk between several APPs and the mononuclear phagocyte system 
(MPS) in the resolution of inflammation, to restore tissue integrity and function. In fact, 
monocyte-derived dendritic cells (Mo-DCs), an integral component of the MPS, play a 
fundamental role both in the regulation of antigen-specific adaptive responses and in 
the development of immunologic memory and tolerance, particularly in inflammatory 
settings. Due to their high plasticity, Mo-DCs can be modeled in vitro toward a tolero-
genic phenotype for the treatment of aberrant immune-inflammatory conditions such as 
autoimmune diseases and allotransplantation, with the phenotypic outcome of these 
cells depending on the immunomodulatory agent employed. Yet, recent immunotherapy 
trials have emphasized the drawbacks and challenges facing tolerogenic Mo-DC gen-
eration for clinical use, such as reduced therapeutic efficacy and limited in vivo stability 
of the tolerogenic activity. In this review, we will underline the potential relevance and 
advantages of APPs for tolerogenic DC production with respect to currently employed 
immunomodulatory/immunosuppressant compounds. A further understanding of the 
mechanisms of action underlying the moonlighting immunomodulatory activities exhib-
ited by several APPs over DCs could lead to more efficacious, safe, and stable protocols 
for precision tolerogenic immunotherapy.
Keywords: acute phase proteins, inflammation, monocyte-derived dendritic cells, tolerance, immunotherapy
iNTRODUCTiON
In the superior organisms, inflammation is considered as an evolutionarily conserved, physiologi-
cal response of the vascularized tissue against external physical, chemical, and biological insults, 
or internal threats such as metabolic stress. This complex, exquisitely fine-tuned and coordinated 
process is engaged with the final goal of restoring the homeostasis and repair/regenerate the dam-
aged tissues in a relatively short-time window (1). Whether the insult persists, chronic undesirable 
inflammation ensues and is associated with a variety of pathologies such as autoimmune processes 
or vascular diseases. Innate immune cells with the capacity for antigen presentation, that is, 
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specialized antigen-presenting cells (APCs) such as monocytes/
macrophages and dendritic cells (DCs), are key players in all 
phases of inflammation (2). Thus, APCs are involved in the 
initial sensing of noxious agents through recognition of danger-
associated molecular patterns (DAMPs), including pathogen-
associated molecular patterns (PAMPs), in the amplification 
of the defense/protection by locally attracting other immune cells 
through the vasculature and, finally, are essential effector cells in 
the resolution of inflammation. All these events are orchestrated 
mainly by DCs, endowed with high plasticity to bridge innate and 
acquired immune responses within the inflammatory program 
(3, 4). Local DAMPs/PAMPs detection by pattern recognition 
molecules (PRMs), notably the toll-like receptor (TLR) family of 
proteins, in these cells initiates an adaptive immune process lead-
ing to the activation and expansion of antigen-specific effector 
T lymphocytes in the secondary lymphoid organs (5). Conver-
sely, the absence of pro-inflammatory stimuli or engagement of 
particular immunoreceptors, such as co-inhibitory receptors 
(PD-L1, PD-L2, B7-H3, ILT3, etc.) or other tyrosine-based inhibi-
tory motif-containing receptors by a variety of signals maintain 
DCs in an “immature-like” state. These, “immature” DCs are able 
to elicit generalized or antigen-specific unresponsiveness/toler-
ance in central lymphoid organs or in the periphery, promoting 
the further stimulation of T cells (Treg) able to regulate or suppress 
other T cells (6). Such actions are crucial to maintain or return 
to immune homeostasis and to prevent autoimmune responses.
Another inherent aspect of the innate immunity elicited in 
wounded hosts (particularly those severely injured by trauma or 
microbial infection), in parallel to the advent of the above-described 
cellular or acquired immune response, is the prompt occurrence 
of a prominent non-specific immune-inflammatory response 
involving systemic physiological and metabolic altera tions and 
affecting tissues/organs distant to the injured site, namely, the 
acute phase response (7). Thus, immunological stress induces a 
pro-inflammatory cytokine “storm,” diffusing into the circulation 
and alerting the liver, which in turn reinforces a protective response 
through coordinated, cytokine-driven transcriptional changes in 
hepatocytes, leading to the secretion of a variety of molecules that 
limit tissue injury and participate in host defense, termed acute 
phase proteins (APPs), such as the prototypical C-reactive protein 
(CRP), serum amyloid P (SAP), and serum amyloid A (SAA). 
These proteins have been traditionally explored as diagnostic/
prognostic biomarkers reflecting the presence and intensity of 
inflammation during infection or injury. Indeed, while most APPs 
have been traditionally viewed as having a pro-inflammatory 
function, for example, in immune cell recruitment for efficient 
pathogen clearance (8), more recent studies are suggesting that a 
variety of APPs, depending on the microenvironment and through 
molecular mechanisms not yet completely understood, are able to 
interact directly with mononuclear phagocytes inducing a regula-
tory phenotype to these cells.
Mirroring the recent success and increasing importance of 
cellular immunotherapy strategies for cancer, in the last years a 
substantial effort has been devoted to generate DCs from blood 
precursors with tolerogenic features for the treatment of autoim-
mune diseases, allergy, and transplantation. As the first phase I 
adoptive tolerogenic DC therapy clinical trials are being concluded, 
preliminary lessons learned include the overall safety of tolero-
genic DC administration, although also highlight present limita-
tions regarding its efficacy. Thus, important current challenges 
to overcome for a more effective therapeutic outcome include 
the achievement of antigen-specific tolerogenic responses and, 
particularly, the maintenance of a “stable” tolerogenic phenotype 
of the infused DCs regardless of the inflammatory microenviron-
ment that they may confront. Therefore, more progress has to be 
achieved on the thorough characterization, using both in in vitro 
functional readouts and preclinical assays, of tolerogenic DCs 
generated through alternative immunomodulatory inducers able 
to increase their clinical performance in immune-inflammatory 
pathologies.
In this review, we will consider the potential of APPs as novel 
immunomodulators. We will overview the current knowledge 
regarding the interaction of relevant APPs with phagocytes, fun-
damentally monocytes, and monocyte-derived DCs (Mo-DCs), 
resulting in a bias toward immune tolerance. A better under-
standing of the crosstalk between the innate and the adaptive 
immune systems in homeostasis and inflammatory pathology, 
taking into account the unique roles of both APPs and DCs, may 
support therapeutic benefits of APP-induced tolerogenic DCs for 
transplantation and autoimmunity.
THe ACUTe PHASe ReSPONSe AT  
THe CROSSROADS BeTweeN iNNATe 
AND ADAPTive iMMUNiTY
The immediate innate body defense against acute illnesses, that is, 
the acute phase response, features both, hepatic and extra-hepatic 
overproduction and release, typically within 24–48 h after the ini-
tial insult, of a variety of seemingly biochemically and functionally 
unrelated APPs into the circulation. In fact, phagocyte sentinels 
(macrophages, DCs, and neutrophils) sensing eminently damaged, 
stressed or infected cells, elicit a local pro-inflammatory response, 
and seek further help by secreting pro-inflammatory cytokines 
such as IL-6, IL-1, IL-8, TNF-α, and IFN-γ, and releasing a large 
assortment of “alarmins.” These key mediators travel through the 
circulation, induce neuroendocrine and behavioral changes (fever, 
hyponatremia, anorexia, somnolence, and lethargy), and reach the 
liver, whose most abundant cell type, the hepatocytes, hold also the 
capability to act as immunological agents and have a central role 
in the systemic innate immune response through the intravascular 
secretion of APPs (9). Indeed, APPs conform up to 40 different 
proteins whose serum concentration increase (positive APPs) or 
decrease (negative APPs) at least 25% in response to inflamma-
tion (10). Positive APPs include soluble PRMs [CRP, SAP, SAA, 
lipopolysaccharide binding protein, complement components, 
and α1 acid glycoprotein (AAG)], hemostasis factors (fibrino-
gen, plasminogen, prothrombin, and plasminogen activators), 
binding/transport proteins [haptoglobin (Hp), hemopexin, and 
ceruloplasmin], and antiproteases [α1-antichymotrypsin (AAC), 
antithrombin (AT), α1-antitrypsin (AAT), and α2-macroglobulin 
(α2M)]. These proteins participate in host defense (e.g., attracting 
inflammatory cells, inactivating proteolytic enzymes, activating 
complement, opsonizing, and clearing infectious agents) and 
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limit tissue injury (scavenging free radicals and modulating the 
host’s immune response). Conversely, negative APPs comprise 
albumin, AT, transferrin, transthyretin, transcortin, and retinol-
binding protein (8). It has been suggested that reduced albumin 
production enhances the amino acids “pool” available for positive 
APP production, and that decreased transferrin production could 
protect the host by starving microorganisms of the iron required 
for growth and virulence expression (11).
Based on their degree of response to inflammatory stimuli, 
APPs can be grouped as strong (more than 100-fold increase in 
blood levels; CRP, α2M, SAA), moderate (2–10-fold increase; 
haptoglobulin, fibrinogen, AAT), or weak (up to twofold increase; 
C3, ceruloplasmin). While strong APPs usually increase abruptly 
within the first 24–48 h after an acute inflammatory event, and 
further experience a quick decline related to their relatively short 
half-life, moderate to weak APPs are more likely present during 
chronic inflammatory processes. According to the differential 
regulation of their synthesis by cytokines, positive APPs can also 
be classified in type I and type II. Type I are induced by IL-1-like 
pro-inflammatory cytokines (SAA, CRP, C3, AAG, and SAP), and 
type II are induced by IL-6-like cytokines (fibrinogen, Hp, AAC, 
AAT, and α2M). In turn, the production of hepatic APPs may 
also be influenced by other cytokines and by hormones (insulin, 
dexamethasone, glucagon, and/or epinephrine) (12). Thus, at the 
level of the organism, the complex neuroendocrine-immunolog-
ical axis seems to efficiently modulate the acute phase response 
through various feedback loops (13). For instance, cytokines 
released from monocytes/macrophages activated locally through 
noxious inflammatory agents stimulate the brain to release stress-
response neuropeptides such as corticotropin (ACTH), which 
acts into the adrenal glands inducing glucocorticoid production. 
Glucocorticoids can downregulate pro-inflammatory cytokines 
(IL-1, TNF-α).
Due to their stability in the circulation compared with cyto-
kines, which are cleared from the circulation within a few hours, 
several APPs have been extensively used as diagnostic/prognostic 
biomarkers because their increased/decreased levels reflect the 
presence and intensity of inflammation during infection or injury, 
remaining unchanged for 48 h or longer. Nevertheless, although 
presenting high sensitivity, the diagnostic value of APPs is being 
questioned due to their low specificity (14).
iNFLAMMATORY DCs iN iNFLAMMATiON
Relevant features of the acute phase response are an increase 
in the number of peripheral leukocytes and the dilation and 
leakage of the vasculature through the release of inflammatory 
mediators such as reactive oxygen species, arachidonate metabo-
lites, and pro-inflammatory cytokines and chemokines (15). 
Pro-inflammatory cytokines activate and mobilize blood cell 
precursors in both bone marrow and peripheral blood (16–18). 
Moreover, stimulated endothelial cells allow the extravasation 
and migration of circulating leukocytes. Among these, Mo-DCs 
have been appealing due to: (1) their influence on adaptive 
immune function and rapid accumulation in the inflammatory 
focus and (2) their easy ex vivo isolation, amplification, and 
manipulation. Mo-DCs arise from monocyte precursors both 
in  vitro and in  vivo (19, 20). Monocytes are recruited to sites 
of inflammation, having a major role in the protective immune 
response of the host (21). For instance, local differentiation of 
monocytes into inflammatory macrophages and DCs is induced 
in response to natural killer cell-produced IFN-γ (22). In fact, by 
depletion of tissue-resident cell populations it has been shown 
that circulating monocyte precursors in the blood can replen-
ish functionally specialized macrophages and DCs (23), which 
reinforces the concept of blood monocytes as reservoirs that can 
be utilized on demand, particularly in inflammatory processes 
where monocyte recruitment is strongly increased. Accordingly, 
monocytes have been shown to migrate to inflammatory sites 
and differentiate into DCs in various murine models of inflam-
mation (24, 25). Sequential trafficking and/or differentiation 
of the different monocyte subsets to the sites of inflammation 
is likely modulated by diverse mechanisms (26–28). Following 
tissue damage, classical monocytes (human: CD14++CD16−; 
mouse: Ly6C+CCR2highCX3CR1low) appear to be recruited within 
the first few hours, after their egression from the bone marrow 
being modulated by the CCR2–CCL2/CCL7 axis (29). Once in 
the inflammatory milieu, they differentiate into DCs and mac-
rophages and exert a potent pro-inflammatory immune response 
through high-level production of IL-1β and TNF-α, among 
other protective functions (30–32). When the progression of 
the immune-inflammatory response is not halted, the prolonged 
action of classical inflammatory monocytes may result in tissue 
damage and drive autoimmunity (33). Several days after the 
initial damaging insult, acute inflammation enters in a resolu-
tion phase where the classical monocyte levels are reduced and 
progressively replaced by intermediate [CD14+(+)CD16+] and 
non-classical (human: CD14+CD16++; mouse: Ly6C−CCR2low 
CX3CR1high) monocytes, which relay on the CX3CR1–CX3CL1 
axis to accumulate in the damaged tissue and, after DC/mac-
rophage differentiation, secrete anti-inflammatory cytokines 
(IL-10, TGF-β) that counteract tissue injury and promote wound 
healing (34). Certainly, it has been suggested that, in response to 
inflammatory stimuli, patrolling non-classical CD16-expressing 
monocytes could leave the blood vessels and function as DC 
precursors (35). Thus, these inflammatory Mo-DCs seem to hold 
unique features influenced by the microenvironmental status of 
the inflamed tissue, boosting more potent immune responses 
DCs derived from classical monocytes, and better immune 
tolerance DCs generated from non-classical monocytes (36).
Monocytes from human or mouse peripheral blood or bone 
marrow are widely utilized to generate in vitro large amounts of 
Mo-DCs upon differentiation, typically with IL-4 and GM-CSF 
(37), allowing comprehensive mechanistic studies regarding their 
key role in the immune-inflammatory processes at the molecular 
level and to initiate DC therapy approaches in the clinic. In fact, 
a comparative transcriptional profiling has revealed that human 
DCs isolated from inflammatory fluids are the in vivo counterpart 
of in vitro-generated Mo-DCs from CD14+ monocytes (38), in 
the same way that murine inflammatory DCs share equivalent 
developmental and functional features to in  vitro GM-CSF/ 
IL-4-induced BM-DCs (39).
Monocyte-derived cells have been deemed essential for induc ing 
protective Th1 cell-mediated immunity following both pathogen 
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infection and non-infectious conditions (40, 41), and may acquire 
DC-specific functions such as cross-presentation (41, 42).
Conversely, DCs play a key role in tolerance, whether partici-
pating in the negative selection of autoreactive T cells in the thy-
mus (central tolerance) (43), or limiting effector T cells through 
deletion or anergy and, instead, promoting Treg differentiation 
(peripheral tolerance). A variety of mechanisms are orchestrated 
by DCs to induce tolerance and suppress inflammatory responses 
against innocuous stimuli, including the overexpression of inhibi-
tory immunoreceptors (e.g., PD-L1, B7H, and CD80/86), the 
ligand-activated transcription factor aryl hydrocarbon receptor, 
the pore-forming cytolytic protein perforin, and the release and/
or control of several immunomodulatory mediators, such as anti-
inflammatory cytokines (IL-10, IL-27, and TGF-β), indoleamine 
2,3-dioxygenase (IDO) metabolites, retinoic acid, vitamins A 
and D, ATP, and adenosine [see Ref. (44, 45), and references 
therein]. The regulatory function of DCs is determined by their 
maturation/activation status (46). Hence, tolerogenic DCs hold 
an “immature” or “semi-mature” state.
A myriad of recent studies has reported the in vitro generation 
of monocyte-derived “permissive,” “tolerogenic,” “regulatory,” 
“alternatively activated,” or “maturation-resistant” cell types (47), 
although most attention has been focused on Mo-DCs. This is 
being achieved by incubation with a variety of different biological 
or pharmacological agents such as cytokines (IL-10, TNF-α, IFN-γ, 
TGF-β, IL-21, and thymic stromal lymphopoietin), immunosup-
pressant drugs (dexamethasone, tacrolimus, and mycophenolate), 
organic molecules (vitamin D3, salycilate, vasoactive intestinal 
peptide, intravenous immunoglobulin, and hepatocyte growth 
factor), other agents (pathogen products, mesenchymal stem 
cells), or their combinations, or by genetic engineering (48–50). 
Mimicking the in  vivo circumstances, the resulting tolerogenic 
Mo-DCs are characterized essentially by reduced surface expres-
sion of co-stimulatory molecules (CD80, CD86, and CD40) and 
maturation markers (CD83), increased expression of inhibitory 
receptors (ILT3, PD-L1, and PD-L2), reduced or null produc-
tion of pro-inflammatory cytokines (IL-12, TNF-α, IFN-γ, and 
IL-8) and, conversely, increased production of anti-inflammatory 
cyto kines (IL-10, TGF-β), even in the presence of inflammation 
(51–54). Thus, the main features of these cells would be to present 
a state of unresponsiveness through hampering key activation/
maturation pathways such as the pro-inflammatory NF-κB 
pathway, and to support the differentiation and maintenance of 
different types of Treg cells.
TOLeROGeNiC ACTiONS  
OF APPs ON DCs
There are clear evidences showing that the acute phase response 
can directly influence the differentiation of DCs toward a tolero-
genic state. In sepsis, an overwhelming systemic inflammatory 
response syndrome, an expansion of intermediate monocytes 
has been detected in the circulation (55). Monocytes from sepsis 
patients preferentially differentiated into alternative CD1a− DCs, 
holding increased capacity to induce Foxp3+ Treg cells, when 
compared with monocytes from healthy individuals in which 
classical monocytes predominated (56). On the other hand, the 
hepatic APPs SAA and Cxcl1/KC cooperatively promoted 
myeloid-derived suppressor cell (MDSC) mobilization, accumu-
lation and survival, reversed dysregulated inflammation, and 
restored survival of mice deficient for gp130 (the signaling receptor 
shared by IL-6 family cytokines) undergoing polymicrobial sepsis 
(57). Thus, hepatocytes may also modulate innate immune cells 
through the acute phase response, for example, by recruitment 
and promotion of MDSC function.
Accordingly, it is not unreasonable to consider a number of 
APPs, acting either systemically or locally in a restricted time 
window coinciding with a parallel increase of monocyte recruit-
ment toward the inflammatory focus, as a part of a protective 
network to restrain the harmful consequences of continued 
overinflammation. That is, APPs could directly exert a feedback 
loop redirecting the differentiation of these inflammatory mono-
cytes to regulatory or tolerogenic DCs, in an attempt to regain 
homeostasis and maintain tissue integrity through the resolution 
of the immune-inflammatory response (Figure 1). We will now 
focus in representative APPs and APP-related proteins that are 
able to induce tolerogenesis through modulation of Mo-DC dif-
ferentiation and/or maturation.
Soluble PRMs are a heterogeneous group of molecules (col-
lectins, ficolins, pentraxins, and other complement components) 
belonging to the humoral arm of innate immunity that have been 
proposed to represent the functional ancestor of antibodies (58). 
They share basic functions with the membrane-bound PRMs from 
DCs, such as the recognition of “non-self ” and “modified self ” and, 
additionally, play an important role in opsonization and comple-
ment activation. In the last years, several studies have evidenced 
that APPs, particularly soluble PRMs, acting directly in the early 
stages of monocyte differentiation mediated by GM-CSF/IL-4 
(a faithful in vitro model for the generation of inflammatory DCs), 
are able to confer a tolerogenic phenotype and function to the 
ensuing Mo-DCs, although the detailed molecular mechanisms 
of APPs action over DCs are still not known for most of them.
In the next paragraphs, we will address the state of under-
standing and arguments regarding APP-mediated tolerogenic 
DC generation and functional outcome, according to common 
features currently defining tolerogenic DCs.
Pentraxins
Pentraxins constitute a superfamily of evolutionarily conserved 
multimeric and multifunctional proteins sharing an 8-amino 
acid “pentraxin domain” (HxCxS/TWxS, where “x” is any amino 
acid) in their carboxy terminus. Based on the primary structure 
of the promoter, pentraxins are divided into short pentraxins 
(CRP and SAP) and long pentraxins (PTX3) (58). Both CRP and 
SAP are homooligomeric proteins arranged in a ~25 kDa subunit 
pentameric radial symmetry and hold 51% amino acid sequence 
identity. They constitute the main APPs in human and mouse, 
respectively, are produced by hepatocytes and have wide capacity 
for pathogen recognition, phagocytosis, and cytokine secretion 
through interaction with Fcγ receptors (59). Moreover, CRP and 
SAP are able to regulate the activation of the complement system 
by interaction with C1q, ficolins, C4b-binding protein (C4BP) 
and factor H, favoring efferocytosis and preventing the onset of 
autoimmune diseases (60, 61).
FiGURe 1 | Physiological involvement of C4b-binding protein (C4BP)(β−) in cell-mediated immune-inflammatory responses. According to this model, at the 
steady-state, the classical and lectin pathways complement inhibitor C4BP circulates in two main isoforms: C4BP(β+) (80%) and C4BP(β−) (20%) (1). Strong 
pro-inflammatory conditions (acute phase) induce a modification of the C4BP(β+):C4BP(β−) ratio to 50:50, through increased levels of the acute phase protein 
C4BP(β−) (2). Several evidences support a specific action of overexpressed C4BP(β−) over inflammatory monocytes and monocyte-derived dendritic cells (DCs). 
Strong inflammatory stimuli (infection, lupus nephritis, etc.) trigger the presence of inflammatory monocytes in the blood, which are actively recruited to inflamed 
tissues, and differentiated to inflammatory DCs, having the ability to stimulate naïve T cells. Under these conditions, besides its function as complement inhibitor,  
the increased presence of C4BP(β−) in the blood would act in one or both ways upon engaging one or some, as yet unknown, cell surface receptor(s): 1) reducing 
transendothelial migration and accumulation of the inflammatory monocytes into the inflamed tissue and 2) inducing a tolerogenic phenotype in the recruited 
inflammatory DCs, which would led to: (a) inhibition of T cell proliferation and differentiation into Th1, Th2, and/or Th17 cells depending on the inflammatory 
microenvironment, (b) decreased pro-inflammatory cytokine secretion (IL-12, TNF-α, IFN-γ, etc.), (c) reduced migration to the lymph nodes, and conversely,  
to: induction of anti-inflammatory cytokine release (IL-10, TGF-β, etc.), and (d) Treg generation within the inflamed tissues (3).
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C-reactive protein has been shown to transform biological 
functions of Mo-DCs toward a tolerogenic phenotype. Interes-
tingly, when CRP was added at the early stage of Mo-DC differ-
entiation from CD14+ monocytes, it downregulated surface 
expression of DC-SIGN and the antigen uptake molecules CD205 
and CD206, resulting in reduced endocytosis capacity (62, 63). 
Moreover, LPS-mediated Mo-DC maturation was also impaired, 
through downregulation of co-stimulatory molecules CD80 and 
CD86, and of the maturation marker CD83, inhibition of allogeneic 
T cell proliferation and decreased production of pro-inflammatory 
cytokines (IL-12, IL-8, IL-6, TNF-α, MIP-1α, MIP-1β, and MCP-1). 
These effects seemed to be mediated through the immunoreceptor 
FcγRII/CD32, which is downregulated during differentiation into 
Mo-DCs. Conversely, another study reported just the opposite, 
that is, CRP was able to activate Mo-DCs through upregulation 
of DC activation markers (CD40, CD80, CD83, and CCR7) and 
induced allogeneic T cell proliferation and IFN-γ production (64). 
Nevertheless, in that case the pulsation of Mo-DCs was started 
at day 6 of culture, once the Mo-DCs were fully differentiated. 
These results evidence the restricted tolerogenic activity window 
characterizing CRP, at the initial steps of Mo-DC differentiation. 
Analogously, human SAP has been reported to bind strongly to 
monocytes but weakly to differentiated Mo-DCs (65). SAP also 
inhibits neutrophil recruitment and monocyte to fibrocyte differ-
entiation, in part, by binding to the FcγRs (66, 67), and polarizes 
macrophages toward an immunoregulatory phenotype through 
PI3K/Akt-ERK signaling (68). Thus, SAP regulates key compo-
nents of the innate immune system and inflammation.
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Pentraxins is a multimeric 340 kDa glycoprotein with a complex 
quaternary structure (elongated, with a large and a small domain 
interconnected by a stalk region) composed of two tetramers 
linked by interchain bridges to form an octamer. PTX3 expression 
is induced in a variety of cell types (particularly in phagocytes) 
by inflammatory cytokines, TLR agonists or pathogens, binds to 
a wide range of microorganisms, and plays a relevant role in host 
defense and inflammation (69), for example, by regulating leuko-
cyte recruitment (70). Moreover, analogously to CRP and SAP, 
PTX3 is also able to modulate the activation of the complement 
system by binding C1q, ficolins, mannose-binding lectin (MBL), 
and the complement regulators C4BP and FH, and increases 
phagocytosis in an FcγRII-dependent manner. Hence, PTX3 
binds to apoptotic cells and recruits C4BP, limiting complement 
activation and an exacerbated inflammatory response (71). In this 
context, PTX3 reduces the release of TNF-α and IL-10 by LPS-
challenged Mo-DCs, and consistently inhibits the upregulation 
of membrane molecules (CD86, HLA-ABC, HLA-DR) on an 
inflammatory cell surface induced by LPS. Moreover, PTX3 also 
induces macrophages to secrete anti-inflammatory cytokines such 
as TGF-β and IL-10 (72), modulates LPS-induced inflammatory 
response and attenuates liver injury (73).
Complement Components
The evolutionarily conserved complement system, in addition to 
its crucial function in the innate defense against common patho-
gens, holds also a key regulatory non-immunogenic role in the 
“silent” clearance of immune complexes from the circulation and 
apoptotic cells from damaged tissues, in close crosstalk with the 
mononuclear phagocyte system (74). We have recently discussed 
the “non-canonical” activities of a variety of complement effec-
tors and modulators able to transform DCs toward a tolerogenic 
phenotype (75). Thus, we will instead focus here on the functional 
outcome of a few representative complement components directly 
interacting with Mo-DCs.
In addition to their central role as complement cascade initia-
tors for microbial phagocytosis and killing, it is becoming evident 
that both, complement cascade initiators such as mannose-
binding lectin (MBL) and soluble complement inhibitors such 
as C4BP, are able to promote an immunomodulatory and anti-
inflammatory environment by direct interaction with DCs and 
other immune cells.
MBL, the prototypic initiator of the lectin pathway of comple-
ment activation, belongs to the collectin family and, through its 
carbohydrate-recognition domains, is able to bind to oligosac-
charides (mannose, N-acetyl-glucosamine) on the pathogen 
surface (76). DCs from MBL-deficient individuals showed 
increased IL-6 production and poor allogeneic T cell responses, 
features of pathogen-stimulated DCs, which could be reversed by 
in vitro addition of MBL (77). In fact MBL, at supraphysiological 
concentrations, influences the phenotype and function of DCs 
by attenuating LPS binding to immature DCs and their further 
maturation and pro-inflammatory cytokine production (IL-12, 
TNF-α), while preventing allogeneic T lymphocyte proliferation 
(78). Moreover, MBL not only attenuates LPS-induced Mo-DC 
maturation, but also affects early Mo-DC differentiation from 
CD14+ monocytes, yielding Mo-DCs with tolerogenic features 
(low MHC-II, CD80 and CD40 expression, increased IL-10 and 
IL-6 secretion, and reduced T cell alloproliferation), and being 
possibly mediated by members of the STAT family (79).
Among the complement inhibitors, the regulator of the classical 
and lectin pathways of complement activation C4BP has a com-
plex oligomeric structure. The major C4BP isoform, C4BP(β+), 
has an heterooligomeric radial structure (570  kDa). It is com-
posed by seven identical 70 kDa modular α-chains (responsible 
for the complement inhibitory activity, and for pentraxin, hep-
arin, DNA, and pathogen binding, among others), and a single 
40  kDa β-chain (high-affinity binding site for anticoagulant 
vitamin K-dependent Protein S, allowing a strong interaction 
with apoptotic/necrotic cells) (80, 81). The minor C4BP isoform, 
C4BP α7β0 or C4BP(β−), holds the same oligomeric structure 
and complement inhibitory function than C4BP(β+), but lacks 
the β-chain. Under acute phase conditions (poly-traumatisms, 
sepsis) the levels of circulating C4BP(β−) isoform increase sig-
nificantly as a consequence of the differential hepatic regulation 
of the α- and β-chains by pro-inflammatory cytokines (82). Thus, 
C4BP(β−) is a genuine APP. We have shown that the C4BP(β−) 
isoform, but not the C4BP(β+) isoform, by direct interaction 
with Mo-DCs through as yet unknown receptor(s), only in the 
early stages of monocyte to Mo-DC differentiation, is able to 
confer an anti-inflammatory, tolerogenic phenotype to these 
cells, retaining a high-endocytic activity, and morphological fea-
tures of immaturity. Upon LPS priming, these C4BP(β−)-treated 
Mo-DCs featured low-surface expression of CD83, CD80, and 
CD86, inhibition of pro-inflammatory IL-12, TNF-α, IFN-γ, 
IL-6, and IL-8 production and, instead, increased expression 
of anti-inflammatory IL-10 and TGF-β, reduced CCR7 expres-
sion and chemotaxis, and promoted Treg expansion. Moreover, 
C4BP(β−) induced tolerogenic DCs with increased viability and 
yield when compared with the immunomodulator vitamin D3, 
and similarly prevented T cell alloproliferation (83).
Although perhaps not a bona fide APP, C1q, the recognition 
unit from the classical pathway of complement activation and 
major component of the C1 complex, binds to various APPs 
including CRP, SAP, and PTX3, thereby regulating the classical 
complement pathway. C1q has also been recognized to modulate 
cellular functions within the adaptive immune response (84). 
Certainly, C1q has even been proposed as a tolerogenic DC 
marker because relevant immunomodulatory agents such as 
dexamethasone, IL-10, or vitamin D3 are able to induce at least a 
10-fold overexpression of C1q at both mRNA and protein levels 
in Mo-DCs (85). The regulatory effects of C1q on monocyte/
DC precursors could be mediated by gC1qR, occurring within 
a narrow timeframe of monocyte to Mo-DC transition and being 
influenced by the microenvironment. Accordingly, while in the 
presence of danger signals C1q would recognize and bind anti-
gens through its globular head domains, leading to activation of a 
pro-inflammatory immune response in immature Mo-DCs, in the 
absence of danger signals C1q would maintain immature Mo-DCs 
in a tolerance state through gC1qR (86). Certainly, gC1qR liga-
tion on the surface of Mo-DCs suppresses TLR4-induced IL-12 
production through PI3K pathway activation (87). Furthermore, 
an alternative mechanism of C1q-mediated immunomodulation 
involves high-affinity binding between C1q and the inhibitory 
7
Serrano et al. APPs for Tolerogenic DC Generation
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 892
immunoreceptor LAIR-1, which inhibits monocyte-to-Mo-DC 
differentiation (88). More recently, this interaction has been 
refined through the characterization of a tri-molecular engage-
ment encompassing C1q-CD33/LAIR-1 crosslinking (89).
Hemoglobin- and iron-Binding Proteins
Essential cellular processes, such as energy generation, DNA rep-
lication, oxygen transport, and protection from oxidative stress 
are dependent on iron. Since bacterial pathogens also require iron 
for replication and infection, iron sequestration strategies from 
vertebrates constitutes a significant form of nutritional innate 
immunity (90). Thus, in homeostatic healthy conditions iron is 
largely intracellular and sequestered within ferritin. Conversely, 
acute inflammatory processes such as infection, include the 
release of lactoferrin from secondary granules contained within 
polymorphonuclear leukocytes. Furthermore, hemoglobin rele-
ased by physiological and pathological hemolysis is captured by 
Haptoglobin (Hp). All together, these proteins ensure a virtually 
free iron environment in vertebrate tissues.
Ferritin is a major tissue iron-binding protein with a molecu-
lar weight of 500 kDa, whose main function is to store iron in a 
soluble non-toxic form, protecting the cell from iron-mediated 
redox reactions. The levels of this APP remain elevated in many 
chronic inflammatory diseases such as periodontitis (91). Ferritin 
is composed of 24 subunits consisting of heavy (H) and light (L) 
chains, and may heterooligomerize forming isoferritins depend-
ing on the proportions of H and L chains (92). The immunosup-
pressive effects of cancer cell supernatants, such as melanoma 
supernatants, correlated with their content of H-ferritin. Acco-
rdingly, H-ferritin has been shown to inhibit anti-CD3-stimulated 
lymphocyte proliferation, probably mediated by increased IL-10 
production (93). Importantly, H-ferritin is also able to induce 
a semi-mature, tolerogenic phenotype on Mo-DCs featuring 
increased expression of CD86 (B7-2) and B7-H1, and the activa-
tion of IL-10-producing Treg cells (94).
Lactoferrin, also known as lactotransferrin, is produced in a 
number of tissues and is frequently found in mucosal secretions 
and neutrophil secretory granules (95). This 80 kDa iron-binding 
glycoprotein is an important component of innate immunity, 
and holds a key role in the protection of mucosal surfaces from 
microbial infections (96). Lactoferrin also modulates innate and 
adaptive immune-inflammatory responses, including cytokine 
production, promotion of T and B cell maturation, and enhance-
ment of delayed-type hypersensitivity against defined antigens. 
Moreover, it has been suggested that lactoferrin might exert adju-
vant activity, enhancing DC function to promote generation of 
antigen-specific T cells (97). In contrast, bovine lactoferrin (bLF) 
seems to play an opposite role. Thus, Mo-DCs differentiated in the 
presence of bLF showed a fully tolerogenic or immunomodula-
tory behavior [potent anti-inflammatory activity, high-endocytic 
capacity, increased expression of molecules with negative immu-
noregulatory functions (ILT3, PD-L1, IDO, and SOCS3), CCL1 
production, and impaired capacity to undergo activation and to 
promote Th1 responses]. bLF is internalized and seems to reach 
the nucleus, although the molecular details mediating the bLF-
mediated transcriptional regulation of Mo-DC differentiation are 
still unknown (98, 99).
Hp is the major hemoglobin-binding protein in plasma. 
This APP, whose hepatic expression is induced by inflamma-
tory mediators such as IL-6-type cytokines, interacts with free 
hemoglobin neutralizing and restricting its oxidative damage 
to various organs (100). Hp has been suggested to exert immu-
nomodulatory effects constituent with suppression of lymphocyte 
function (101). During physiological and pathological hemo-
lysis, the Hp-CD163-heme oxygenase (HO-1) pathway efficiently 
scavenges and circumvents hemoglobin/heme-induced toxicity. 
This pathway plays an anti-inflammatory role in phagocytes, and 
the resulting heme metabolites, such as bilirubin, reinforce its 
cytoprotective and anti-inflammatory efficacy (102). Hp seems 
also to prevent epidermal Langerhans cells from spontaneously 
undergoing functional maturation in the skin, inhibiting their 
capacity to activate autologous T cells in vitro (103).
Other APPs and APP-Related Proteins
Serum amyloid A is an APP produced mainly by the hepato-
cytes, but also by other cell types such as macrophages, smooth 
muscle cells, chondrocytes, epithelial cells, and adipocytes, 
under pro-inflammatory stimuli (58). SAA interacts with Gram-
negative bacteria and, through its opsonic activity, increases 
their phagocytosis and the production of TNF-α and IL-10 
by phagocytes (104). SAA has also been recently shown to be 
involved in the expression of the “alarmin” IL-33 by monocytes 
and macrophages (105). Notably, it has been recently shown that 
SAA-stimulated monocytes (HLA-DRhi HVEMlo) most resemble 
immature Mo-DCs, and are able to drive Treg proliferation (106). 
SAA is also a chemoattractant for immature Mo-DCs through 
formyl peptide receptor like 1/formyl peptide receptor 2 (107). 
Furthermore, mice lacking SAA3, an acutely expressed isoform 
found in non-primate mammals, develop metabolic dysfunc-
tion, and exacerbated pro-inflammatory responses from innate 
immune cells. Particularly, bone marrow-derived DCs from 
SAA3(−/−) mice produce increased levels of IL-1β, IL-6, IL-23, and 
TNF-α in response to LPS compared with cells from wild-type 
mice (108). Thus, endogenous SAA3 likely modulates metabolic 
and immune homeostasis.
α1-Antitrypsin, a member of the SERPIN superfamily of pro-
tease inhibitors, is a major inhibitor of the neutrophil-derived 
serine proteases [neutrophil elastase (NE), cathepsin G, and pro-
teinase 3]. It has a primary anti-inflammatory role by irreversible 
binding and inactivation of NE, protecting the lung against the 
destructive effects of NE released by degranulating neutrophils 
during inflammation (109). AAT is predominantly produced by 
the liver, and its secretion, increased under acute phase condi-
tions, is mediated by pro-inflammatory cytokines (IL-6, IL-1β, 
and TNF-α) (12). Recent studies have reported tolerogenic activi-
ties of AAT that are difficult to explain solely by serine-protease 
inhibition or by its anti-inflammatory actions (110). Circulating 
AAT is bound to lipoprotein particles (LDL and HDL) and docks 
onto lipid-rafts. Thus, TLR2 and TLR4 contained in lipid-rafts 
from macrophages and DCs are downregulated by AAT (111). 
Moreover, AAT induces a tolerogenic phenotype on DCs charac-
terized by low levels of CD40, CD86, and MHC class II, increased 
production of IL-10 and enhanced generation of Tregs through 
a so far unknown mechanism. These tolerogenic DCs maintain, 
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nevertheless, the inflammation-driven cell migration capacity 
(112). In fact, AAT monotherapy has been shown to induce 
tolerance in islet allograft and kidney transplantation (113, 114), 
graft-versus-host disease (115), improved islet function in type I 
diabetes (116), and attenuated lupus nephritis (117).
Fibrinogen is synthesized mainly by hepatocytes, and its 
level increases substantially during infections and inflammatory 
conditions. This 340 kDa glycoprotein, made up of two identi-
cal subunits joined together by disulfide bonds, functions as a 
blood coagulation factor, supporting platelet aggregation, and 
fibrin cloth formation at the site of vessel injury. Fibrinogen had 
an Mo-DC maturation effect comparable with poly I:C, TNF-
α, and PGE2, but it failed to induce IL-12 production (118). 
On the other hand, it has been recently reported that fibrinogen 
cleavage products generated by protease allergens, through 
induction of IL-13 production by mast cells, increased the 
number of TH2-favorable (PD-L2+) DCs in allergic asthma 
(119). Interestingly, another member of the fibrinogen-related 
protein superfamily, soluble fibroleukin or fibrinogen-like 
protein 2 (sFGL2), highly inducible by IFN-γ and with features 
of APP, has a 50 kDa weight and is highly expressed in cytotoxic 
T cells and Tregs upon activation (120). sFGL2 seems to act as an 
immunosuppressor, repressing the proliferation of alloreactive 
T lymphocytes and the maturation of DCs (121, 122). Thus, by 
binding to FcγRIIB and FcγRIII, sFGL2 can adjust the antigen 
presentation ability of APCs. Accordingly, the levels of Th2 
cytokines and the activity of DCs have found to be increased in 
FGL2-deficient mice (123).
iMMUNOTHeRAPeUTiC POTeNTiAL OF 
APPs FOR TOLeROGeNiC DC iNDUCTiON
Pharmacological immunosuppression has gone mainstream of 
past and, still, current therapeutic strategies to prevent transplant 
rejection and to restore autoantigen tolerance in autoimmune 
disorders. Yet, the downside of the immunosuppressive regimens 
is the appearance of numerous and often severe side effects 
and increased risk of infection as a consequence of the general 
suppression of the host immune system (124–126). Thus, the 
attractive concept of using DCs, central orchestrators of other 
immune cells, with the aim to modulate immune-inflammatory 
responses that have gone awry while leaving protective immunity 
intact is becoming gradually a reality in the clinical setting. 
In fact, in addition to being explored in experimental animal 
models of autoimmune diseases such as collagen-induced arth-
ritis (127, 128), diabetes (129, 130), and experimental autoim-
mune encephalomyelitis (EAE) (131), along with experimental 
graft rejection after transplantation (132, 133), tolerogenic DCs 
have recently been, and are currently being tested in phase I 
clinical trials for alloimmune (transplantation, graft-versus-host 
disease) and autoimmune processes (type I diabetes, rheumatoid 
arthritis, multiple sclerosis, and Crohn’s disease), and allergy, and 
there are ongoing collaborative efforts to harmonize/standardize 
tolerance-inducing therapies for upcoming trials (134–136).
The identification, characterization and, most notably, isola-
tion and amplification of genuine regulatory or tolerogenic DCs 
populating a given healthy or diseased tissue, much like MDSCs, 
has proven a daunting task and a real limitation when planning 
to adoptively transfer them for therapeutic benefit. Therefore, 
due to the high plasticity of mononuclear myeloid cells such 
as monocytes, well-established ex vivo protocols of monocyte 
to Mo-DC expansion and differentiation, relying in the use 
of inflammatory cytokines (GM-CSF and IL-4) have become 
instrumental to adopt Mo-DCs as therapeutic cell products for 
clinical use (137).
A central aspect for the successful clinical application of 
tolerogenic Mo-DC relates to their development and manufacture. 
As previously stated, a variety of agents have been employed in vitro 
to skew Mo-DCs toward a tolerogenic or regulatory phenotype 
(notably vitamin D3, immunosuppressive drugs-like dexametha-
sone, or NF-κB inhibitors), opposing their “natural” tendency to 
be activated in vivo in a pro-inflammatory environment. Yet limited 
efficacy has been reported in terms of disease outcome, although 
most trials have noted an increase in Treg levels in the recipient’s 
blood during tolerogenic Mo-DC administration (138–140). 
Clearly, maintaining tolerogenic Mo-DCs in an activation- or mat-
uration-resistant state is a fundamental requirement for a successful 
tolerogenic Mo-DC therapy, because unstable tolerogenic Mo-DCs 
able to reverse back in vivo to an immunogenic phenotype in con-
tact with a pro-inflammatory microenvironment could aggravate 
the pathology. Indeed, semi-mature DCs, considered tolerogenic 
in in vitro assays, may become immunogenic when administered 
in vivo (141, 142). Furthermore, it has been recently reported that 
continuous treatment of DCs during their differentiation from 
bone marrow cells (10-day treatment) with the histone deacetylase 
inhibitor suberoxylanilide hydroxamic acid generated tolerogenic 
DCs that, however, were not stable and, therefore, inefficacious 
when administered in mice with EAE (143). Hence, the possibility 
to anticipate and modulate the stability of tolerogenic Mo-DCs 
in vivo, particularly in the pro-inflammatory allo- or autoimmune 
environments in which these cells are applied, would enhance 
their therapeutic efficacy. As yet, there is not enough mechanistic 
knowledge to ascertain which stimuli guarantee the induction of 
stable tolerogenic Mo-DCs adapted to particular in vivo situations. 
Still, in tolerogenic Mo-DC conditioning protocols, establishing 
the appropriate timing and intensity of the tolerogenic reagent 
treatment, its toxicity, as well as the migration capacity of the 
resulting conditioned cells are crucial aspects to take into account 
for a successful Mo-DC-based immunotherapy (134). For example, 
both rapamycin- and dexamethasone-conditioned cell cultures 
have been shown to markedly reduce DC recovery (144, 145). 
Importantly, none of the APPs proved cytotoxic in the Mo-DC 
cultures, most likely because of the wide range of physiological 
concentrations that these proteins are able to reach in serum, 
fluctuating between homeostatic and acute phase conditions. 
Thus, APP-derived tolerogenic Mo-DCs might overcome some 
of the limitations of the current tolerogenic Mo-DCs employed 
for immunotherapy approaches regarding consistency, safety, and 
efficacy (124, 146).
On the other hand, the common tolerogenic moonlighting 
activity of APPs over Mo-DCs seems surprising, given the variety 
of different physiological functions ascribed to these proteins. 
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TABLe 1 | Immunomodulatory actions of acute phase proteins (APPs) on dendritic cells (DCs).








Annular, ring-shaped, pentameric protein (~125 kDa) Activation of the complement 
system
Pathogen protection
CD209↓, CD40↓, CD83↓, CD80↓, CD86↓
Endocytosis↓





Annular, ring-shaped, pentameric protein (~125 kDa) Activation of the complement 
system
Binding to fibrils and amyloid 
deposits
Pathogen protection
IL-12↓, IL-10↑ (65, 66, 68)
Pentraxin 3 Cyclic multimeric structure. Complex quaternary structure composed 
of two tetramers linked by interchain bridges to form an octamer 
(~340 kDa).
Proposed stabilized decameric protein (~450 kDa)








Oligomeric apolipoprotein. Probably trimeric (~35 kDa) or hexameric 
structure (~70 kDa)








Oligomer (400–700 kDa). Tetrameric structure build of subunits 
containing three presumably identical peptide chains
Activation of the lectin pathway of 
complement
CD40↓, CD80↓






Oligomeric radial structure composed of seven identical α-chains 
(~520 kDa)
Inhibition of the classical pathway of 
complement
CD83↓, CD80↓, CD86↓





α1-antitrypsin Monomer (52 kDa) Serine-protease inhibition CD40↓, CD86↓, MHC-II↓






Haptoglobin Preproprotein processed to yield both α- and β-chains, which 
combine to form a tetramer (~100 kDa), or polymerize (~900 kDa), 
depending on its phenotype
Free plasma hemoglobin binding MHC-I↓, MHC-II↓, B7↓, CD40↓
IL-12↓
Autologous, naive T cell activation↓
(103)
Hemostasis
Fibrinogen Composed of three non-identical pairs of disulfide-bonded chains 
(~340 kDa)
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multi-modular structure (Table 1), providing flexibility in their 
capacity for binding, with a different grade of specificity, a variety 
of humoral and/or cellular determinants, including different 
receptors in the surface of Mo-DCs. This feature might constitute 
an advantage for the fine-tuning of the desired tolerogenic phe-
notype on Mo-DCs.
Another key aspect of APP action, as outlined in previous 
sections, relates to the simultaneous presence and increased 
levels of both APPs and Mo-DCs under overwhelming immune- 
inflammatory conditions such as the acute phase response, which 
incites a physiological crosstalk between these humoral (APPs) 
and cellular (Mo-DCs) systems with the common goal of providing 
protection and progress toward the resolution of inflammation. 
In this regard, APPs probably contribute in vivo to mononuclear 
phagocyte switching toward an anti-inflammatory mode aimed at 
restoration of tissue integrity and function. Consequently, the APP 
interaction with Mo-DCs will be safer and effective over a wide 
range of concentrations, according to the significantly increased 
blood levels reached by APPs under acute phase conditions. 
On the other hand, most APPs have been shown to act over a 
narrow window within the Mo-DC differentiation and/or matura-
tion program, limiting also their hypothetical toxicity, if any, and 
increasing their specificity compared with some of the current 
immunosuppressive/immunomodulatory agents, which need to 
be present over the full differentiation/maturation program to 
induce a tolerogenic outcome into Mo-DCs. Furthermore, seve-
ral APPs and, particularly, all soluble PRMs, operate only in the 
early stages of monocyte to Mo-DC differentiation, while IL-10, 
for example, is active on Mo-DCs up to their terminal differen-
tiation, when Mo-DCs downregulate the IL-10 receptor (147). 
This restricted activity of APPs at the beginning of the Mo-DC 
differentiation program may induce a more permanent and stable 
modification of the Mo-DC tolerogenic phenotype than that 
achieved by immunomodulators/immunossupressors influenc-
ing Mo-DCs late in their differentiation process, or by agents 
affecting only their maturation/activation status. These last agents 
may be more prone to be influenced by the pro-inflammatory 
microenvironment that the tolerogenic Mo-DCs face upon clini-
cal administration. Comparing the performance and outcome 
of in vitro assays, APPs seem to hold a tolerogenic activity over 
Mo-DCs (low expression of co-stimulatory molecules, low pro-
duction of pro-inflammatory cytokines, increased release of 
anti-inflammatory cytokines, low T  cell alloproliferation and, 
instead, increased Treg generation, etc.) at least as efficient as the 
agents (rapamycin, dexamethasone and/or vitamin D3, NF-κB 
inhibitors, etc.) currently employed to generate clinical-grade 
tolerogenic Mo-DCs for the induction or restoration of immune 
tolerance in autoimmune pathologies and transplantation (148). 
Furthermore, given the broadened presence that APPs can reach 
in serum under acute phase conditions and the present hurdles 
facing adoptive DC-based immunotherapy (time-consuming, 
expensive, and arduous to implement in the current regulatory 
environment), the direct in vivo administration of APPs, either 
naked or complexed with nanoparticles, may become a useful 
and efficacious alternative in inflammatory pathologies. In fact, 
nanoparticle formulations for DC-specific receptor targeting 
(DEC205, DC-SIGN, CD40, CD11c, etc.) are being used in 
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preclinical assays and phase I clinical trials as vaccines for onco-
immunotherapy (149–151).
Nevertheless, presently the most important drawback for the 
use of APPs as tolerogenic agents lies in the fact that the detailed 
molecular mechanisms of action of APP-mediated transforma-
tion of Mo-DCs toward a tolerogenic phenotype are not known 
for most of these proteins. Thus, current efforts employing high-
throughput genomics and proteomics approaches will certainly 
dissect cell surface-interacting partner(s) and relevant signaling 
and metabolic pathways underlying APP-mediated programming 
and distinctive functional outcome of the ensuing tolerogenic 
Mo-DCs (152, 153).
CONCLUSiON AND PROSPeCTS
For a successful tolerogenic immunotherapy, Mo-DC condition-
ing must regulate antigen-specific immune responses in the 
intrinsically complex pro-inflammatory environments evolving 
in autoimmune disorders and transplantation, sustaining the 
development of immunological memory toward tolerance. Thus, 
it is critically important to thoroughly test the performance of 
novel tolerance-inducing agents regarding the potency and dura-
bility of the ensuing tolerogenic Mo-DC phenotype.
Besides being proposed as useful biomarkers for a variety of 
inflammatory pathologies, recent studies have proposed that APPs 
play important roles in tissue homeostasis and repair following 
overwhelming immune-inflammatory processes, probably in close 
interaction with inflammatory monocytes and DCs. In fact, APPs 
are able to generate tolerogenic Mo-DCs in vitro with the desired 
regulatory features (increased expression of immunomodulatory 
molecules, enhanced production of anti-inflammatory cytokines, 
and Treg generation) and low immunogenicity (Table 1), compa-
rable with the currently used clinical tolerogenic Mo-DC-inducing 
immunomodulatory/immunosuppressive agents. Although the 
precise mechanism of action of tolerogenic Mo-DC skewing 
induced by most APPs is still unknown, these proteins may prove 
useful alternatives to overcome the present limitations for a more 
efficacious, safe, and stable Mo-DC-based tolerogenic immu-
notherapy. In this regard, attractive attributes of APPs include a 
physiological basis regarding their interaction with Mo-DCs in the 
context of the acute phase response, and a wide range of action 
due to the own intrinsic features of APPs, which would ensure 
reduced toxicity at the cellular level and increased safety upon 
in vivo administration. Moreover, the narrow activity window in 
the early stages of monocyte to Mo-DC differentiation shown by 
several APPs, notably soluble PRMs, should increase specificity 
and, more importantly, may contribute to a more stable tolerogenic 
phenotype. APPs targeting differentiating Mo-DCs could turn 
these cells unresponsive to the in vivo pro-inflammatory microen-
vironment present in autoimmune or alloimmune conditions and, 
therefore, refractory to Mo-DC maturation. Furthermore, taking 
into account novel findings, such as the proteomic characteriza-
tion of tissue-/disease-specific posttranslational modifications of 
APPs (14), or the influence of the clinical status of the Mo-DC 
recipient (154) may fine-tune the tolerogenic potential of APP-
treated Mo-DCs, e.g., their ability to modulate T cell responses. 
Nevertheless, additional research should help clarify whether 
some APPs, particularly pentraxins, or complement activators, 
are able to maintain their induced tolerogenic DCs in a stable and 
functional state upon administration in complex pathological tis-
sue contexts, because of the dual protective and pro-inflammatory 
role played by these multifaceted molecules in physiology.
Definitely, although further work is warranted to establish 
which method, or perhaps combination of methods, is most 
suitable to generate tolerogenic Mo-DCs in the clinical setting, 
APPs may contribute, either on their own, combined with cur-
rently employed immunomodulators/immunosuppressants (155), 
and/or with recently proposed tolerogenic DC boosters such as 
minocycline (156), or reinforcing the tolerogenic properties of 
iPSC-derived CD141+ DCs holding enhanced capacity for antigen 
cross-presentation (157), to the design of tailored protocols to 
induce or re-establish immunological tolerance in different clini-
cal settings including allogeneic transplantation and autoimmune 
diseases.
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